FMP

FMP

Enter

ARCT - Arcturus Therapeutic...

Financial Summary of Arcturus Therapeutics Holdings Inc.(ARCT), Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccine

photo-url-https://financialmodelingprep.com/image-stock/ARCT.png

Arcturus Therapeutics Holdings Inc.

ARCT

NASDAQ

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

29.87 USD

-0.63 (-2.11%)

About

ceo

Mr. Joseph E. Payne M.Sc.

sector

Healthcare

industry

Biotechnology

website

https://arcturusrx.com

exchange

NASDAQ

Description

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therap...

CIK

0001768224

ISIN

US03969T1097

CUSIP

03969T109

Address

10628 Science Center Drive

Phone

858 900 2660

Country

US

Employee

180

IPO Date

May 22, 2013

Summary

CIK

0001768224

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

03969T109

ISIN

US03969T1097

Country

US

Price

29.87

Beta

2.65

Volume Avg.

509.94k

Market Cap

804.45M

Shares

-

52-Week

17.52-43.81

DCF

-27.2

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-7.41

P/B

-

Website

https://arcturusrx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ARCT News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep